Itziar Otano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3081416/publications.pdf

Version: 2024-02-01

471371 552653 1,677 34 17 26 h-index citations g-index papers 36 36 36 2982 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy. International Review of Cell and Molecular Biology, 2022, , 163-192.	1.6	3
2	Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors. , 2021 , 9 , $e001587$.		10
3	CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. Nature Communications, 2021, 12, 7296.	5. 8	22
4	Scavenger Receptor Class B Type I is Required for 25â€Hydroxycholecalciferol Cellular Uptake and Signaling in Myeloid Cells. Molecular Nutrition and Food Research, 2020, 64, e1901213.	1.5	1
5	CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. Immunity, 2020, 52, 856-871.e8.	6.6	387
6	Cellular cytotoxicity is a form of immunogenic cell death. , 2020, 8, e000325.		61
7	Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death. Theranostics, 2020, 10, 4481-4489.	4.6	24
8	Abstract 1698: Cellular cytotoxicity is a form of immunogenic cell death. Cancer Research, 2020, 80, 1698-1698.	0.4	1
9	Twists and turns to translating 4-1BB cancer immunotherapy. Science Translational Medicine, 2019, 11, .	5 . 8	31
10	Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature, 2019, 569, 428-432.	13.7	313
11	Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. Cancer Cell, 2019, 36, 613-629.e7.	7.7	99
12	Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity. Cell Stress, 2019, 3, 236-239.	1.4	17
13	Abstract 2331: Intratumor adoptive transfer of IL-12 mRNA transiently engineered anti-tumor CD8+ T cells. , 2019, , .		0
14	CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs. Frontiers in Immunology, 2018, 9, 2618.	2.2	86
15	Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. Molecular Therapy, 2018, 26, 2553-2566.	3.7	20
16	Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy. Cancer Research, 2017, 77, 3672-3684.	0.4	99
17	TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis. Scientific Reports, 2017, 7, 5514.	1.6	14
18	Complementary Effects of Interleukin-15 and Alpha Interferon Induce Immunity in Hepatitis B Virus Transgenic Mice. Journal of Virology, 2016, 90, 8563-8574.	1.5	22

#	Article	IF	CITATIONS
19	Genetically Engineering HBV-Specific CD8+ T Cells Resistant to Trail-Mediated Apoptosis. Journal of Hepatology, 2016, 64, S513-S514.	1.8	0
20	Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8ÂT Cells in the Same Host. Cell Reports, 2016, 16, 1243-1252.	2.9	176
21	Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I. Journal of Hepatology, 2015, 63, 329-336.	1.8	21
22	804 MODULATION OF REGULATORY T CELLS ACTIVITY IN COMBINATION WITH IL-12 INDUCES A REBOUND EFFECT INCREASING THE TOLEROGENIC LIVER ENVIRONMENT IN CHRONIC VIRAL HEPATITIS. Journal of Hepatology, 2012, 56, S314.	1.8	0
23	Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B. Hepatology, 2012, 56, 474-483.	3.6	23
24	Characterization of woodchuck apolipoprotein Aâ€k: A new tool for drug delivery and identification of altered isoforms in the woodchuck chronic hepatitis model. Journal of Medical Virology, 2011, 83, 1221-1229.	2.5	5
25	Development of a Liver-specific Tet-On Inducible System for AAV Vectors and Its Application in the Treatment of Liver Cancer. Molecular Therapy, 2011, 19, 1245-1253.	3.7	51
26	Identification of CD4+ and CD8+ T cell epitopes of woodchuck hepatitis virus core and surface antigens in BALB/c mice. Vaccine, 2010, 28, 5323-5331.	1.7	4
27	Treatment of Chronic Viral Hepatitis in Woodchucks by Prolonged Intrahepatic Expression of Interleukin-12. Journal of Virology, 2009, 83, 2663-2674.	1.5	34
28	Treatment of Pancreatic Cancer With an Oncolytic Adenovirus Expressing Interleukin-12 in Syrian Hamsters. Molecular Therapy, 2009, 17, 614-622.	3.7	84
29	Semliki Forest Virus Expressing Interleukin-12 Induces Antiviral and Antitumoral Responses in Woodchucks with Chronic Viral Hepatitis and Hepatocellular Carcinoma. Journal of Virology, 2009, 83, 12266-12278.	1.5	42
30	543 EVALUATION OF SEMLIKI FOREST VIRUS (SFV) VECTORS EXPRESSING IL-12 FOR TREATMENT OF HEPADNAVIRUS-INDUCED HEPATOCELLULAR CARCINOMA (HCC) IN WOODCHUCKS. Journal of Hepatology, 2009, 50, S201.	1.8	0
31	574 ISOLATION, CHARACTERIZATION AND INHIBITION OF WOODCHUCK REGULATORY T CELLS. Journal of Hepatology, 2009, 50, S211.	1.8	О
32	Characterization of highâ€capacity adenovirus production by the quantitative realâ€time polymerase chain reaction: a comparative study of different titration methods. Journal of Gene Medicine, 2008, 10, 1092-1101.	1.4	11
33	[410] HEPADNAVIRUS NUCLEOCAPSID PROTEIN INHIBITS CD4+ T CELL RESPONSE IN VITRO AND IN VIVO. Journal of Hepatology, 2007, 46, S158.	1.8	0
34	Gene therapy for viral hepatitis. Expert Opinion on Biological Therapy, 2006, 6, 1263-1278.	1.4	5